IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

被引：0
|
作者：
Hiddemann, W. [1 ]
Barbui, A. M. [2 ]
Albendea, M. A. Canales [3 ]
Cannell, P. K. [4 ]
Collins, G. P. [5 ]
Duerig, J. [6 ]
Forstpointner, R. [1 ]
Herold, M. [7 ]
Hertzberg, M. [8 ]
Klanova, M. [9 ,10 ,11 ]
Radford, J. A. [12 ,13 ]
Tobinai, K. [14 ]
Burciu, A. [15 ]
Fingerle-Rowson, G. R. [11 ]
Nielsen, T. [11 ]
Wolbers, M. [16 ]
Marcus, R. E. [17 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Med 3, Munich, Germany
[2] Azienda Osped Papa Giovanni XXIII, Dept Hematol, Bergamo, Italy
[3] Hosp Univ la Paz, Dept Med, Madrid, Spain
[4] Fiona Stanley Hosp, Dept Haematol, Murdoch, WA, Australia
[5] Churchill Hosp, Oxford Canc & Haematol Ctr, Dept Clin Haematol, Oxford, England
[6] Univ Klinikum Essen, Med Fac Haematol, Essen, Germany
[7] HELIOS Klinikum Erfurt, Ctr Oncol, Erfurt, Germany
[8] Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia
[9] Charles Univ Prague, Fac Med 1, Gen Hosp, Prague, Czech Republic
[10] Charles Univ Prague, Inst Pathol Physiol, Prague, Czech Republic
[11] F Hoffmann La Roche Ltd, Pharma Dev Clin Oncol, Basel, Switzerland
[12] Univ Manchester, Manchester, Lancs, England
[13] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[14] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[15] F Hoffmann La Roche Ltd, Pharma Dev Safety & Risk Management, Basel, Switzerland
[16] F Hoffmann La Roche Ltd, Pharma Dev Biometr Biostat, Basel, Switzerland
[17] Kings Coll Hosp London, Dept Haematol, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S775
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [21] Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)
    Ujjani, Chaitra S.
    Jung, Sin-Ho
    Pitcher, Brandelyn
    Martin, Peter
    Park, Steven I.
    Blum, Kristie A.
    Smith, Sonali M.
    Czuczman, Myron S.
    Davids, Matthew S.
    Leonard, John P.
    Cheson, Bruce D.
    BLOOD, 2015, 126 (23)
  • [22] A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
    Laurie H. Sehn
    Maurizio Martelli
    Marek Trněný
    Wenxin Liu
    Christopher R. Bolen
    Andrea Knapp
    Deniz Sahin
    Gila Sellam
    Umberto Vitolo
    Journal of Hematology & Oncology, 13
  • [23] Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
    Sahn, Laurie H.
    Martelli, Maurizio
    Trneny, Marek
    Liu, Wenxin
    Bolen, Christopher R.
    Knapp, Andrea
    Sahin, Deniz
    Sellam, Gila
    Vitolo, Umberto
    BLOOD, 2019, 134
  • [24] A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
    Sehn, Laurie H.
    Martelli, Maurizio
    Trneny, Marek
    Liu, Wenxin
    Bolen, Christopher R.
    Knapp, Andrea
    Sahin, Deniz
    Sellam, Gila
    Vitolo, Umberto
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [25] A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma
    Othman, Tamer
    Rosenberg, Aaron S.
    Timmerman, John
    Heyman, Benjamin
    Abdulhaq, Haifaa
    Tuscano, Joseph M.
    BLOOD, 2022, 140 : 11954 - 11955
  • [26] Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis
    Bellone, Marco
    Pradelli, Lorenzo
    Molica, Stefano
    De Francesco, Adele Emanuela
    Ghislieri, Daniela
    Guardalben, Emanuele
    Caputo, Antonietta
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 661 - 671
  • [27] A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma
    Jurczak, Wojciech
    Ilidia, Moreira
    Govindbabu, Kanaka Setty
    Eduardo, Munhoz
    Ascuncion, Echeveste Maria
    Giri, Pratyush
    Nelson, Castro
    Juliana, Pereira
    Luiza, Akria
    Sergey, Alexeev
    Dzhelil, Osmanov
    Pultar, Philippe
    Cherfi, Azzeddine
    Zhu, Peijuan
    Amersdorffer, Jutta
    BLOOD, 2016, 128 (22)
  • [28] Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study
    Marcus, Robert E.
    Davies, Andrew J.
    Ando, Kiyoshi
    Klapper, Wolfram
    Opat, Stephen
    Owen, Carolyn J.
    Phillips, Elizabeth H.
    Sangha, Randeep
    Schlag, Rudolf
    Seymour, John F.
    Townsend, William
    Trneny, Marek
    Wenger, Michael K.
    Fingerle-Rowson, Gunter
    Rufibach, Kaspar
    Moore, Tom
    Herold, Michael
    Hiddemann, Wolfgang
    BLOOD, 2016, 128 (22)
  • [29] COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
    Bellone, M.
    Pradelli, L.
    Friggi, E.
    Caputo, A.
    VALUE IN HEALTH, 2019, 22 : S465 - S466
  • [30] Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma
    Canales, Miguel A.
    Buchholz, Thomas A.
    Mason, James R.
    Parreira, Joana M.
    Tomiczek, Monique S.
    Hubel, Kai
    BLOOD, 2019, 134
12345